MissionIR would like to highlight CytRx Corp. (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology. The company’s pipeline is focused on the clinical development of aldoxorubicin (formerly known as INNO-206), its improved version of the widely used chemotherapeutic agent doxorubicin. The Company also has rights to two additional drug candidates, tamibarotene and bafetinib.
In the company’s news,
Seeking Alpha yesterday published the following article featuring CytRx: http://seekingalpha.com/article/1700372-cytrx-corporation-remains-an-undiscovered-opportunity-inthe-cancer-space?source=yahoo#comments_header
Released On: 4/8/2016
Views: 3856
Released On: 4/7/2016
Views: 4597
Released On: 3/31/2016
Views: 3589
Released On: 3/24/2016
Views: 2922
Released On: 3/17/2016
Views: 2483
Released On: 3/11/2016
Views: 2327
Released On: 3/4/2016
Views: 2620
Released On: 3/3/2016
Views: 2321
Released On: 2/23/2016
Views: 3673
Released On: 2/12/2016
Views: 2678
Released On: 2/10/2016
Views: 2389
Released On: 2/9/2016
Views: 2547
Released On: 1/20/2016
Views: 4329
Released On: 1/14/2016
Views: 4795
Released On: 1/5/2016
Views: 3024
Released On: 12/18/2015
Views: 9356
Released On: 12/9/2015
Views: 2789
Released On: 12/3/2015
Views: 3236